Business Context and Reporting Period
Company: NOVAVAX INC
Filing Type: Form 8-K (Current Report)
Date of Report: April 11, 2019
Event: Notice of potential delisting from The Nasdaq Stock Market due to failure to meet the minimum bid price requirement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on stock listing compliance.
Material Changes
- Stock Price Deficiency: The Company's common stock closed below the $1.00 per share minimum required for continued listing on The Nasdaq Global Market for 30 consecutive business days prior to April 11, 2019.
- Compliance Period: Nasdaq has granted a 180-day compliance period ending October 8, 2019, to regain compliance.
- Delisting Risk: If the stock does not close at $1.00 or higher for 10 consecutive business days within the compliance period, the securities will be subject to delisting.
Guidance, Outlook, and Management Commentary
- Proposed Remedy: The Company has scheduled a Special Meeting of stockholders for May 8, 2019, to consider a 1-for-20 reverse stock split.
- Expected Outcome: Management expects the reverse stock split, if approved, to increase the bid price of the common stock to meet the $1.00 threshold.
- Contingency Plan: If the reverse split is not approved or fails to achieve compliance, the Board of Directors will consider other options to meet the requirement before the October 8, 2019 deadline.
Investor Verification Checklist
- Verify the outcome of the Special Meeting of stockholders scheduled for May 8, 2019, regarding the 1-for-20 reverse stock split.
- Monitor the daily closing bid price of NOVAVAX common stock to ensure it reaches $1.00 for 10 consecutive business days before October 8, 2019.
- Review any subsequent filings for alternative compliance strategies if the reverse split is rejected or ineffective.